Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCL


Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.

Diego Villa, MD, FRCPC, of BC Cancer in Vancouver Canada, sat down to discuss induction therapy with bendamustine and rituximab (Rituxan) for transplant eligible and ineligible patients with mantle cell lymphoma (MCL) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.


The analysis shows that you can achieve excellent response rates with an overall response rate of 88% and complete response rate of 55% when you treat all comers with BR (bendamustine and rituximab). In our study there was no difference between those over the age of 65 or under the age of 65 in terms of response rates.

Well, our studies definitely support the use of BR in the transplant ineligible population. Our studies are pretty much in line with the STiL and BRIGHT studies showing improved PFS compared to R-CHOP, and in fact our studies suggest that there might be an overall survival improvement although we included patients treated with CVPR as that was part of our previous standard.

In terms of the transplant eligible patients, our studies suggest that BR is indeed an effective induction regimen for these patients. As you know, there is no defined standard of care in the literature for the front-line therapy of mantle cell lymphoma in transplant eligible patients, and our studies certainly suggest that this could be a reasonable alternative for some patients.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.